HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Walther-Jallow, L. Articles by Thorstensson, R. Search for Related Content PubMed PubMed Citation Articles by Walther-Jallow, L. Articles by Thorstensson, R. Agricola Articles by Walther-Jallow, L. Articles by Thorstensson, R.

Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys

Swedish Institute for Infectious Disease Control and Microbiology and Tumour Biology Centre, Karolinska Institute, SE-17182 Solna, Sweden¹
Immunopathology Laboratory, Karolinska Institute, SE-10401 Stockholm, Sweden²
Department of Virology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands³

Author for correspondence: Lilian Walther-Jallow at Department of Immunology, Swedish Institute for Infectious Disease Control, SE-17182 Solna, Sweden. Fax +46 8 337460. e-mail Lilian.Walther.Jallow{at}mtc.ki.se

In this study we compared the efficacy of live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol). Six monkeys were first inoculated intravenously with live HIV-2_SBL-6669 and 7 to 10 months later were challenged intrarectally with 10 MID₅₀ of cell-free simian immunodeficiency virus (SIV) strain SIVsm. One monkey was completely protected against SIV infection and all five monkeys that became SIV-infected showed a lower virus replication and an initial lower virus load as compared with a parallel group of six control animals. In another experiment five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125. The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally. After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection whereas the remaining two macaques became SIV-infected but with limited virus replication. In conclusion, vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only.

This article has been cited by other articles:

				W. W. Yeh, P. Jaru-ampornpan, D. Nevidomskyte, M. Asmal, S. S. Rao, A. P. Buzby, D. C. Montefiori, B. T. Korber, and N. L. Letvin Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate J. Virol., March 15, 2009; 83(6): 2686 - 2696. [Abstract] [Full Text] [PDF]